Evogene Ltd. (EVGN)
NASDAQ: EVGN · Real-Time Price · USD
0.5251
-0.0301 (-5.42%)
At close: Jun 18, 2026, 4:00 PM EDT
0.5101
-0.0150 (-2.86%)
After-hours: Jun 18, 2026, 7:58 PM EDT
Evogene Revenue
Evogene had revenue of $334.00K in the quarter ending March 31, 2026, a decrease of -85.74%. This brings the company's revenue in the last twelve months to $1.84M, down -70.41% year-over-year. In the year 2025, Evogene had annual revenue of $3.85M, down -30.91%.
Revenue (ttm)
$1.84M
Revenue Growth
-70.41%
P/S Ratio
3.04
Revenue / Employee
$35,462
Employees
52
Market Cap
5.60M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 3.85M | -1.72M | -30.91% |
| Dec 31, 2024 | 5.58M | 2.60M | 87.02% |
| Dec 31, 2023 | 2.98M | 1.31M | 78.03% |
| Dec 31, 2022 | 1.68M | 745.00K | 80.11% |
| Dec 31, 2021 | 930.00K | -110.00K | -10.58% |
| Dec 31, 2020 | 1.04M | 287.00K | 38.11% |
| Dec 31, 2019 | 753.00K | -994.00K | -56.90% |
| Dec 31, 2018 | 1.75M | -1.63M | -48.33% |
| Dec 31, 2017 | 3.38M | -3.16M | -48.30% |
| Dec 31, 2016 | 6.54M | -4.59M | -41.23% |
| Dec 31, 2015 | 11.13M | -3.38M | -23.31% |
| Dec 31, 2014 | 14.51M | -3.07M | -17.46% |
| Dec 31, 2013 | 17.58M | 509.00K | 2.98% |
| Dec 31, 2012 | 17.07M | 2.17M | 14.57% |
| Dec 31, 2011 | 14.90M | 2.34M | 18.61% |
| Dec 31, 2010 | 12.56M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BioAtla | 2.00M |
| XTL Biopharmaceuticals | 968.00K |
| Cardio Diagnostics Holdings | 16.57K |
| Pulmatrix | 3.00K |
| Alaunos Therapeutics | 3.00K |
| Soligenix | 2.34K |
EVGN News
- 3 days ago - Evogene Slides: Company presentation - Filings
- 10 days ago - Evogene to Present Its Pharma Division Achievements at the BIO International Convention - PRNewsWire
- 17 days ago - Evogene (EVGN) Completes Phase 1 Trial of BMC128 with Promising Results - GuruFocus
- 17 days ago - Evogene says Phase 1 clinical study of BMC128 met primary endpoint - TheFly
- 17 days ago - Evogene Announces Successful Completion of Phase 1 Clinical Study of BMC128, a Rationally Designed Live Bacterial Product, in Combination with Nivolumab by its Subsidiary Biomica - PRNewsWire
- 24 days ago - Evogene price target lowered to $2.15 from $2.25 at Alliance Global - TheFly
- 4 weeks ago - Evogene Q1 2026 Loss Deepens: -$0.60/Share vs -$0.28 Expected - AlphaStreet
- 4 weeks ago - Evogene Earnings Call Transcript: Q1 2026 - Transcripts